Interleukin-2 therapies have been seen as promising ways to treat solid tumors, but they have proven challenging because of the ability of IL-2 to both activate and suppress the immune system. Their effectiveness has been limited because of potentially toxic side effects, which have included vascular leak syndrome and pulmonary edema. Aulos Biosciences believes the AI-based approach to computational drug design used for its lead experimental therapy allows it to unlock the power of IL-2 without triggering the concerning side effects of existing therapies. We spoke to Aron Knickerbocker, president and CEO of Aulos Bioscience, about the potential for IL-2 therapies to treat solid tumors, the limits of today's IL-2 therapies, and the AI-based design behind its experimental IL-2 therapy in development.
How a Plant-Derived Gel Halts Bleeding in Seconds
Exploiting a Vulnerability in Cancers
Democratizing AI
A Rapid Onset Nasal Spray to Treat Mental Health Conditions
A Regenerative Medicine Company Puts Its Off-the-Shelf Vessel Replacements to the Test in Ukraine
Battling Resistance in Tumors with “Pan-Variant” Kinase Inhibitors
Treating Disease by Editing Genes in the Microbiome
Embracing the Promise of Natural Killer Cells in the Fight Against Cancer
Addressing Neurodegenerative Disease by Suppressing a Hyper Immune Response
Bringing Precision Medicine to Psychiatry
Attacking Neurodegenerative Diseases with Protein Degraders
Restoring Immune Activity While Suppressing Cancer Proliferation
A New Model for Preventing Life-Threatening Blood Clots
The Race to Live Forever
A Model for Moving from Breakthrough to Blockbuster
Building the Next-Generation of Cell and Gene Therapies
Building Small Molecule Drugs that Are Superior to Biologics
A New Class of Cancer Therapies Targets Solid Tumors with a Dual Action
A Pursuit of Off-The-Shelf CAR-T Therapies
Mapping the Human Proteome
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Ground Truths